Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer

The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Seruga, B., Gan, H.K., Knox, J.J.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2009
Materias:
Urologic Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687807/
https://www.ncbi.nlm.nih.gov/pubmed/19478903
_version_ 1782167597276463104
author Seruga, B.
Gan, H.K.
Knox, J.J.
author_facet Seruga, B.
Gan, H.K.
Knox, J.J.
author_sort Seruga, B.
collection PubMed
description The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a need for long interruptions, dose reductions, or permanent discontinuation of the treatment.
format Text
id pubmed-2687807
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Multimed Inc.
record_format MEDLINE/PubMed
spelling pubmed-26878072009-05-28 Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer Seruga, B. Gan, H.K. Knox, J.J. Curr Oncol Urologic Oncology The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a need for long interruptions, dose reductions, or permanent discontinuation of the treatment. Multimed Inc. 2009-05 /pmc/articles/PMC2687807/ /pubmed/19478903 Text en 2009 Multimed Inc. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Urologic Oncology
Seruga, B.
Gan, H.K.
Knox, J.J.
Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer
title Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer
title_full Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer
title_fullStr Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer
title_full_unstemmed Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer
title_short Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer
title_sort managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer
topic Urologic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687807/
https://www.ncbi.nlm.nih.gov/pubmed/19478903
work_keys_str_mv AT serugab managingtoxicitiesandoptimaldosingoftargeteddrugsinadvancedkidneycancer
AT ganhk managingtoxicitiesandoptimaldosingoftargeteddrugsinadvancedkidneycancer
AT knoxjj managingtoxicitiesandoptimaldosingoftargeteddrugsinadvancedkidneycancer

Ejemplares similares